Xyzagen, Inc. Presented Groundbreaking Kv7 Research at Society for Neuroscience Annual Meeting
CHICAGO, IL, October 10, 2024
Xyzagen, Inc., a pharmacokinetics consultancy and boutique CRO presented its internal Kv7 research programs. The successful presentations on neurological disorders highlighted its internal Kv7 research prodrug program at the Society for Neuroscience (SfN) Annual Meeting, held in Chicago, IL, from October 4-9, 2024. The presentations showcased Xyzagen’s cutting-edge work in developing a water soluble Kv7 ion channel opener prodrug, XYG204, for the treatment of status epilepticus, functional neurological seizures as an acute use injectable with >10,000 fold increase in solubility over the active form, ezogabine. The prodrug is also orally available and can be developed under a 505(b)(2) pathway for Focal Onset Seizures. A second prodrug, XYG203, was presented with a focus on efficacy in neuropathic pain with constant absorption throughout the GI tract. This allows for a loading dose and 1/15th daily maintenance doses leading to Cmax to Ctrough swing of 3%, which should substantially reduce TEAEs associated with rapid drug absorption.
Presentation Details
Date: October 4-9, 2024
Location: Chicago, IL, USA
Session: Non-Opoid Treatment for Persistent Pain
Date: October 6, 2024 | 8:00 AM – 9:00 AM CDT | PSTR069.21 / C160
Presenter: Danshina, et al.
Session: Epilepsy: Human Studies
Date: October 7, 2024 | 4:00 PM – 5:00 PM CDT | PSTR205.21 / B33
Presenter: Thrasher, et al.
Xyzagen’s novel Kv7 channel opener prodrugs show promising results in preclinical models of neuropathic pain and epilepsy
Advanced clinical modeling techniques provide insights into potential efficacy and safety profiles in humans
Innovative prodrug approach may offer improved therapeutic window and reduced side effects compared to existing treatments
“Our presentations at the SfN Annual Meeting represent a significant milestone in Xyzagen’s mission to develop novel transformative therapies for patients with neurological disorders based on over 25 years of Kv7 research,”
said Mr. Christopher Crean, Founder and CEO of Xyzagen, Inc. “The positive data from our Kv7 research programs underscore the potential of our prodrug approach for ezogabine and paves the path for our novel Kv7 programs, to address critical unmet needs in neuropathic pain, epilepsy treatment and functional neurological seizures.”
About Xyzagen
Xyzagen augments a client’s pharmacology and pharmacokinetics drug development team. As a leading pharmacokinetics consultancy and contract research organization with wet lab and rodent vivarium facilities, Xyzagen is able to push model informed drug development into its First-in-Rat® and First-in-Mouse® discovery platforms as well as support late-stage clinical noncompartmental PK, PopPK, and Quantitative Medicine.
Our knowledge in pharmacology/pharmacogenomics and in vitro/in vivo pharmacokinetics allows the client to expand their core scientific team during the critical period of candidate selection up to the PreIND meeting and through clinical development and the preNDA meeting. We’re a boutique organization which allows for small clients and CROs to work directly with experts.
